07.13.21 -- The Cell & Gene Talent Crunch, RNA-Engineered Cell Therapy, and Real-Time Clinical Analysis from the Business of Biotech Podcast

Check out the latest episodes from The Business of Biotech, Biotech with the Bozenhardts, and Life Science Connect. As a member of the Life Science Connect community, you have access to content beyond our weekly newsletters, including our podcast series. Don’t forget to subscribe so you never miss an episode!

BridgeBio has a whopping 30+ preclinical to clinical-stage candidates in its pipeline, representing an impressive array of modalities and targets. It boasts a couple of commercial wins under its belt. Central to its success are partnerships with scientists and researchers to fuel pipeline expansion. Here, BridgeBio CBO Michael Henderson, M.D., walks us through the formula behind the company's academia-led growth strategy.

Michael Mehler honed his cell therapy chops at Adaptimmune before joining GSK as senior clinical development manager, cell therapy oncology, in 2017. He and Cell & Gene chief editor Erin Harris joined the Business of Biotech podcast for a candid and detailed discussion on finding, hiring, and retaining cell and gene therapy professionals, facilitating their ongoing training, bridging the gap between academia and industry, why clinical feedback is an underappreciated source of intelligence, and the resources available to cell and gene developers to further their "pipelines" of bench-level talent.

Cartesian president and CEO Murat Kalayoglu, M.D., Ph.D., has led three of his company's six autoimmune, oncology, and respiratory candidates through Phase 1/2 clinical trials, and two others are on the cusp of entering Phase 1 this year. With so many programs in and entering the clinic, he's a great choice for a conversation on GMP expectations for Phase 1 first-in-human trials. Glean insight from Cartesian's experience and learn about the company's novel approach to RNA-engineered cell therapies for oncology and beyond.

Glympse Bio president and CEO Dr. Caroline Loew explores the possibilities and implications of the in-vivo, bioengineered, tunable sensors the company is developing for diagnostic and prognostic purposes in protease-mediates diseases. Currently in the clinic with applications for non-alcoholic steatohepatitis and other fibrotic diseases, as well as non-small cell lung cancer and other solid tumors, Glympse is unlocking an unprecedented view of near-real-time therapeutic response and therapeutic efficacy that could have big implications on the way biologics are developed, refined, and studied in the clinic.

Herman and Erich Bozenhardt have a combined 55 years of bioprocess facilities design and equipment experience, and they’re here to share it all in our fresh Bioprocess with the Bozenhardts podcast series.

According to Outsourced Pharma chief editor, Louis Garguilo, “Politics has never played a bigger role in our (global) biopharma industry.” In this episode, we talk with Louis about three of his recent editorials that touch on this subject while also discussing the current IP debate in pharma and the origins of the coronavirus.

Three biopharmaceutical industry VPs of HR departments discuss the challenges of continued operations amidst COVID-19 initiated lockdowns, along with some of the best practices implemented.

We sat down with three biopharmaceutical industry executives to discuss some of the thinking and actions taken to mitigate risk to their companies’ manufacturing and supply chains amidst a pandemic.

We thought it would be interesting to have a discussion with three biopharmaceutical executives about how they are preparing for this unique 2021 JPM and how those preparations are different than what they’ve done in the past.

Fundraising used to always be done in person. But then COVID-19 hit. From those first virtual pitches that may have been just a little bit “wonky,” biopharma execs have actually become quite proficient at the process and the platforms. Three biopharma execs share some best practices of the virtual pitch.

Considering many Life Science Leader readers daydream of starting and leading their own biopharmaceutical company someday, we thought it would be informative to host an executive virtual roundtable with three biopharmaceutical company CEOs who have done just that.